Review Article

Hypereosinophilic Syndrome: Two Case Reports of Contrasting Variants

Authors: Jared Szymanski, DO, Edward Rappaport, MD

Abstract

Two cases of hypereosinophilic syndrome that illustrate different variants are reported. Recognition of the specific variant is important because the treatments differ. Patients with hypereosinophilic syndrome should be monitored for evidence of a myeloproliferative process because treatment with tyrosine kinase inhibitors in these patients is effective and may prevent significant morbidity.


Key Points


* There are at least two variants of hypereosinophilic syndrome, illustrated by the case reports presented herein.


* It is important to determine which variant a patient has because of differing treatments.


* Tyrosine kinase inhibitors are effective in the myeloproliferative variant, and act by inhibiting a newly described gene fusion product called FIP1L1-PDGFR-α.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.George TI, Arber DA. Pathology of the myeloproliferative diseases. Hematol Oncol Clin North Am2003;17:1101–1127.
 
2.Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Ann Rev Med2003;54:169–184.
 
3.Gotlib J, Cools J, Malone J, et al. The FIP1l1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103:2879–2891.
 
4.Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473–478.
 
5.Brito-Babapulle, F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003;121:203.